A detailed history of Black Rock Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Black Rock Inc. holds 2,546,361 shares of CRSP stock, worth $137 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,546,361
Previous 2,516,486 1.19%
Holding current value
$137 Million
Previous $158 Million 10.17%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$60.67 - $89.12 $1.81 Million - $2.66 Million
29,875 Added 1.19%
2,546,361 $174 Million
Q4 2023

Feb 13, 2024

SELL
$38.62 - $72.18 $7.6 Million - $14.2 Million
-196,724 Reduced 7.25%
2,516,486 $158 Million
Q3 2023

Nov 13, 2023

SELL
$45.39 - $59.0 $243,517 - $316,535
-5,365 Reduced 0.2%
2,713,210 $123 Million
Q2 2023

Aug 11, 2023

SELL
$43.47 - $67.77 $3.48 Million - $5.42 Million
-80,006 Reduced 2.86%
2,718,575 $153 Million
Q1 2023

May 12, 2023

BUY
$41.0 - $56.12 $6.92 Million - $9.48 Million
168,844 Added 6.42%
2,798,581 $127 Million
Q4 2022

Feb 13, 2023

BUY
$39.19 - $65.67 $11.1 Million - $18.6 Million
283,153 Added 12.07%
2,629,737 $107 Million
Q3 2022

Nov 14, 2022

BUY
$61.1 - $83.78 $11.9 Million - $16.3 Million
194,458 Added 9.04%
2,346,584 $153 Million
Q2 2022

Aug 12, 2022

SELL
$43.23 - $73.83 $5.47 Million - $9.35 Million
-126,648 Reduced 5.56%
2,152,126 $131 Million
Q1 2022

May 12, 2022

BUY
$53.19 - $79.24 $53.6 Million - $79.8 Million
1,007,246 Added 79.22%
2,278,774 $143 Million
Q4 2021

Feb 10, 2022

BUY
$70.09 - $111.29 $9.97 Million - $15.8 Million
142,244 Added 12.6%
1,271,528 $96.4 Million
Q3 2021

Nov 09, 2021

BUY
$110.2 - $156.64 $8.68 Million - $12.3 Million
78,736 Added 7.49%
1,129,284 $126 Million
Q2 2021

Aug 11, 2021

BUY
$100.84 - $161.89 $106 Million - $170 Million
1,050,548 New
1,050,548 $170 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $4.19B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.